Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYS-609
- Development stage
- Unknown
- Lead developer
- Eyevensys
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
EYS-609 is a gene therapy drug developed as a **VEGF-A inhibitor** for ophthalmic diseases, specifically targeting choroidal neovascularization associated with conditions such as wet age-related macular degeneration (wet AMD), retinal vein occlusion, and diabetic macular edema. Its mechanism involves gene transfer to inhibit **vascular endothelial growth factor A (VEGF-A)**, thereby preventing abnormal blood vessel growth in the eye. The drug was developed by Eyevensys. As of 2025, the global highest development status of EYS-609 is **Discontinued** in preclinical development, with no active clinical trials for any indication[1][5][7].
02
Targets
Beyond the preview
Go deeper on EYS-609.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYS-609.